Literature DB >> 18095081

Intraperitoneal administration of paclitaxel and oral S-1 for a patient with peritoneal dissemination and hydronephrosis due to advanced gastric cancer.

Shigeyuki Tamura1, Hirofumi Miki, Ken Nakata, Daisuke Takiuchi, Kaoru Okada, Shin Nakahira, Shu Okamura, Keishi Sugimoto, Naohiro Tomita, Yuichi Takatsuka.   

Abstract

We report a patient with type 3 gastric cancer with peritoneal dissemination and hydronephrosis who was successfully treated with intraperitoneal infusion of paclitaxel and oral administration of S-1. He was diagnosed with unresectable gastric cancer with severe peritoneal dissemination by staging laparoscopy. We selected combined chemotherapy with both paclitaxel and S-1. Paclitaxel at 60 mg/m(2) was administered intraperitoneally on days 1 and 8, and S-1 at 100 mg/body was administered orally for 14 days, followed by 7 days' rest, as one course. After five courses, primary tumor reduction was confirmed and no cancer cells were detected on pathocytological investigation at second-look laparoscopy. The patient underwent total gastrectomy with lymph node dissection. He died from liver metastasis 29 months after the initial treatment, but he had not suffered from peritoneal metastases and had kept a good quality of life (QOL) since that treatment. This chemotherapy can be applied as one of the promising candidates for the treatment of patients with peritoneal metastasis of gastric cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18095081     DOI: 10.1007/s10120-007-0431-x

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


  17 in total

1.  The new Japanese Classification of Gastric Carcinoma: Points to be revised.

Authors:  Takashi Aiko; Mitsuru Sasako
Journal:  Gastric Cancer       Date:  1998-12       Impact factor: 7.370

2.  [Pharmacologic study of intraperitoneal paclitaxel in gastric cancer patients with peritoneal dissemination].

Authors:  Sachio Fushida; Nao Furui; Shinichi Kinami; Itasu Ninomiya; Takashi Fujimura; Genichi Nishimura; Tetsuo Ohta; Koichi Yokogawa; Kenichi Miyamoto; Koichi Miwa
Journal:  Gan To Kagaku Ryoho       Date:  2002-11

3.  Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.

Authors:  T Shirasaka; Y Shimamato; H Ohshimo; M Yamaguchi; T Kato; K Yonekura; M Fukushima
Journal:  Anticancer Drugs       Date:  1996-07       Impact factor: 2.248

4.  Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group.

Authors:  W Koizumi; M Kurihara; S Nakano; K Hasegawa
Journal:  Oncology       Date:  2000-04       Impact factor: 2.935

5.  Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.

Authors:  P Francis; E Rowinsky; J Schneider; T Hakes; W Hoskins; M Markman
Journal:  J Clin Oncol       Date:  1995-12       Impact factor: 44.544

6.  Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer.

Authors:  Yutaka Yonemura; Yoshio Endou; Etsurou Bando; Kiyoshi Kuno; Taiichi Kawamura; Masashi Kimura; Tsutomu Shimada; Ken-Ichi Miyamoto; Takuma Sasaki; Paul H Sugarbaker
Journal:  Cancer Lett       Date:  2004-07-16       Impact factor: 8.679

7.  Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-Fluorouracil.

Authors:  Takuji Mori; Yoshiyuki Fujiwara; Masahiko Yano; Shigeyuki Tamura; Takushi Yasuda; Shuji Takiguchi; Morito Monden
Journal:  Oncology       Date:  2003       Impact factor: 2.935

8.  Therapeutic efficacy and toxicity of sequential methotrexate and 5-fluorouracil in gastric cancer.

Authors:  T Konishi; M Hiraishi; K Mafune; T Miyama; T Hirata; K Mori; H Nishina; Y Idezuki
Journal:  Anticancer Res       Date:  1994 May-Jun       Impact factor: 2.480

9.  Neoadjuvant chemotherapy for high-grade advanced gastric cancer.

Authors:  Y Yonemura; T Sawa; K Kinoshita; N Matsuki; S Fushida; S Tanaka; S Ohoyama; T Takashima; H Kimura; T Kamata
Journal:  World J Surg       Date:  1993 Mar-Apr       Impact factor: 3.352

10.  Oral fluoropyrimidine anticancer drug TS-1 for gastric cancer patients with peritoneal dissemination.

Authors:  Harushi Osugi; Nobuyasu Takada; Masashi Takemura; Susumu Kaseno; Sigeru Lee; Masakatsu Ueno; Yoshinori Tanaka; Kennichirou Fukuhara; Yushi Fujiwara; Hiroaki Kinoshita
Journal:  Oncol Rep       Date:  2002 Jul-Aug       Impact factor: 3.906

View more
  6 in total

1.  S-1 plus intravenous and intraperitoneal Paclitaxel for gastric cancer with peritoneal metastasis.

Authors:  Joji Kitayama; Hironori Ishigami; Hironori Yamaguchi; Hiroharu Yamashita; Shigenobu Emoto; Shoichi Kaisaki
Journal:  Gastrointest Cancer Res       Date:  2012-05

2.  Clinical outcome and management of ureteral obstruction secondary to gastric cancer.

Authors:  Kazuhiro Migita; Akihiko Watanabe; Shoji Samma; Takao Ohyama; Hirofumi Ishikawa; Yoriaki Kagebayashi
Journal:  World J Surg       Date:  2011-05       Impact factor: 3.352

3.  Pilot study of a combination of S-1 and paclitaxel for patients with peritoneal metastasis from gastric cancer.

Authors:  Shigeyuki Tamura; Hirofumi Miki; Kaoru Okada; Atsushi Takeno; Kumiko Uji; Atsuko Yoshida; Rei Suzuki; Shin Nakahira; Chiyomi Egawa; Ken Nakata; Shu Okamura; Keishi Sugimoto; Yuichi Takatsuka
Journal:  Gastric Cancer       Date:  2010-07-03       Impact factor: 7.370

4.  Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer.

Authors:  Shigeyuki Tamura; Hirofumi Miki; Kaoru Okada; Tomohiro Miyake; Mio Yoshimura; Rei Suzuki; Shin Nakahira; Ken Nakata; Shu Okamura; Keishi Sugimoto; Yuichi Takatsuka
Journal:  Int J Clin Oncol       Date:  2008-12-18       Impact factor: 3.402

5.  Long-term survival after sequential chemotherapy and surgery for advanced gastric cancer.

Authors:  Takashi Orii; Yukihiko Karasawa; Hiroe Kitahara; Masaki Yoshimura; Motohiro Okumura
Journal:  Int J Surg Case Rep       Date:  2013-08-15

6.  Elevated alpha1-acid glycoprotein in gastric cancer patients inhibits the anticancer effects of paclitaxel, effects restored by co-administration of erythromycin.

Authors:  Yoshinao Ohbatake; Sachio Fushida; Tomoya Tsukada; Jun Kinoshita; Katsunobu Oyama; Hironori Hayashi; Tomoharu Miyashita; Hidehiro Tajima; Hiroyuki Takamura; Itasu Ninomiya; Masakazu Yashiro; Kousei Hirakawa; Tetsuo Ohta
Journal:  Clin Exp Med       Date:  2015-09-10       Impact factor: 3.984

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.